4DMT Announces Presentations at 43rd Annual Scientific Meeting of the American Society of Retina Specialists
4D Molecular Therapeutics (NASDAQ:FDMT) announced two upcoming presentations at the 43rd Annual Scientific Meeting of the American Society of Retina Specialists (ASRS) in Long Beach, CA, from July 30 – August 2, 2025.
The presentations will feature interim results from two clinical trials: the SPECTRA Phase 2a trial evaluating 4D-150 for Diabetic Macular Edema, including 52-week primary endpoint and 60-week analyses, and the PRISM Phase 2b trial evaluating 4D-150 for neovascular Age-related Macular Degeneration with 52-week results. Both presentations will be available on the company's website.
4D Molecular Therapeutics (NASDAQ:FDMT) ha annunciato due presentazioni in programma al 43° Meeting Scientifico Annuale della American Society of Retina Specialists (ASRS) che si terrà a Long Beach, CA, dal 30 luglio al 2 agosto 2025.
Le presentazioni mostreranno i risultati intermedi di due studi clinici: lo studio SPECTRA di Fase 2a che valuta 4D-150 per l’edema maculare diabetico, includendo l’analisi del punto finale primario a 52 settimane e quella a 60 settimane, e lo studio PRISM di Fase 2b che valuta 4D-150 per la degenerazione maculare neovascolare legata all’età con risultati a 52 settimane. Entrambe le presentazioni saranno disponibili sul sito web dell’azienda.
4D Molecular Therapeutics (NASDAQ:FDMT) anunció dos presentaciones próximas en la 43ª Reunión Científica Anual de la American Society of Retina Specialists (ASRS) en Long Beach, CA, del 30 de julio al 2 de agosto de 2025.
Las presentaciones incluirán resultados interinos de dos ensayos clínicos: el ensayo SPECTRA Fase 2a que evalúa 4D-150 para edema macular diabético, incluyendo el análisis del punto final primario a las 52 semanas y a las 60 semanas, y el ensayo PRISM Fase 2b que evalúa 4D-150 para la degeneración macular neovascular asociada a la edad con resultados a 52 semanas. Ambas presentaciones estarán disponibles en el sitio web de la compañía.
4D Molecular Therapeutics (NASDAQ:FDMT)는 2025년 7월 30일부터 8월 2일까지 캘리포니아 롱비치에서 개최되는 제43회 미국 망막 전문의 학회(ASRS) 연례 과학 회의에서 두 건의 발표를 예정하고 있다고 발표했습니다.
이번 발표에서는 두 건의 임상시험 중간 결과를 공개합니다: 당뇨병성 황반부종 치료제 4D-150을 평가하는 SPECTRA 2a상 시험으로, 52주 주요 평가 시점과 60주 분석 결과를 포함하며, 나이 관련 신생혈관성 황반변성 치료제 4D-150을 평가하는 PRISM 2b상 시험의 52주 결과도 발표됩니다. 두 발표 모두 회사 웹사이트에서 확인할 수 있습니다.
4D Molecular Therapeutics (NASDAQ:FDMT) a annoncé deux présentations à venir lors de la 43e réunion scientifique annuelle de l'American Society of Retina Specialists (ASRS) qui se tiendra à Long Beach, Californie, du 30 juillet au 2 août 2025.
Les présentations porteront sur les résultats intermédiaires de deux essais cliniques : l'essai SPECTRA de phase 2a évaluant le 4D-150 pour l'œdème maculaire diabétique, incluant les analyses du critère principal à 52 semaines et à 60 semaines, ainsi que l'essai PRISM de phase 2b évaluant le 4D-150 pour la dégénérescence maculaire néovasculaire liée à l'âge avec des résultats à 52 semaines. Les deux présentations seront disponibles sur le site internet de la société.
4D Molecular Therapeutics (NASDAQ:FDMT) gab zwei bevorstehende Präsentationen auf dem 43. Jahrestreffen der American Society of Retina Specialists (ASRS) in Long Beach, Kalifornien, vom 30. Juli bis 2. August 2025 bekannt.
Die Präsentationen zeigen Zwischenresultate aus zwei klinischen Studien: der SPECTRA Phase-2a-Studie, die 4D-150 bei diabetischem Makulaödem untersucht, einschließlich der 52-Wochen-Hauptendpunkt- und 60-Wochen-Analysen, sowie der PRISM Phase-2b-Studie, die 4D-150 bei neovaskulärer altersbedingter Makuladegeneration mit 52-Wochen-Ergebnissen bewertet. Beide Präsentationen werden auf der Website des Unternehmens verfügbar sein.
- None.
- None.
EMERYVILLE, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced podium presentations at the 43rd Annual Scientific Meeting of the American Society of Retina Specialists (ASRS) being held in Long Beach, CA, from July 30 – August 2, 2025.
ASRS 2025 Presentation Details:
| Title: | Interim Results from the SPECTRA Phase 2a Clinical Trial Evaluating Intravitreal 4D-150 in Adults with Diabetic Macular Edema* |
| Date/Time: | Thursday, July 31, 2025 (11:35 – 11:38 a.m. PT) |
| Presenter: | David Almeida, MD, MBA, PhD, DABO, FRCSC, FASRS, Erie Retina Research, PA |
*Includes 52-week primary endpoint analysis and 60-week analysis (all patients have reached 60 weeks as of the data cutoff date of May 2, 2025)
| Title: | PRISM Phase 2b Clinical Trial Evaluating Intravitreal 4D-150 in Adults with Neovascular Age-related Macular Degeneration: 52-week Results |
| Date/Time: | Friday, August 1, 2025 (11:24 – 11:27 a.m. PT) |
| Presenter: | John A. Wells, MD, FACS, Palmetto Retina Center, SC |
The presentations will also be available on the 4DMT website: https://4dmoleculartherapeutics.com/pipeline/#posters-and-publications
About 4DMT
4DMT is a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. The Company’s lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) with a single, safe, intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. The Company’s lead indication for 4D-150 is wet age-related macular degeneration, which is currently in Phase 3 development, and second indication is diabetic macular edema. The Company’s second product candidate is 4D-710, which is the first known genetic medicine to demonstrate successful delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis after aerosol delivery. 4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, and the 4DMT logo are trademarks of 4DMT.
All of the Company’s product candidates are in clinical or preclinical development and have not yet been approved for marketing by the U.S. Food and Drug Administration or any other regulatory authority. No representation is made as to the safety or effectiveness of the Company’s product candidates for the therapeutic uses for which they are being studied.
Learn more at www.4DMT.com and follow us on LinkedIn.
Contacts:
Media:
Jenn Gordon
dna Communications
Media@4DMT.com
Investors:
Julian Pei
Head of Investor Relations and Corporate Finance
Investor.Relations@4DMT.com
FAQ
When will 4D Molecular Therapeutics (FDMT) present at ASRS 2025?
What clinical trials will FDMT present at ASRS 2025?
Where can investors access FDMT's ASRS 2025 presentations?
What data will be presented in FDMT's SPECTRA trial presentation?
